Lead Product(s) : PBT2
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PBT2 is a low molecular weight drug candidate, orally bioavailable, crosses the blood-brain barrier, it has demonstrated efficacy in individuals with alzheimer’s disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 14, 2023
Lead Product(s) : PBT2
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PBT2
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Professor Colin Masters
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the license agreement, Alterity grants the entire rights to the AH patent as well as an exclusive worldwide license to develop and commercialize both AH and PBT2 (acyl hydrazone) in Alzheimer’s disease (AD).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 14, 2023
Lead Product(s) : PBT2
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Professor Colin Masters
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : PBT2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Alterity Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Alterity and UniQuest to Reverse Bacterial Resistance to Antibiotics
Details : The licensed technology combines Alterity’s PBT2 and other zinc ionophores with commonly used antibiotics to treat infections caused by multidrug resistant bacteria. This is an opportunity for Alterity to further leverage its investment in PBT2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 21, 2020
Lead Product(s) : PBT2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Alterity Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : PBT2
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Absorption, Metabolism and Excretion Study of [14C]PBT2 and Absolute Bioavailability of PBT2
Details : PBT2 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 26, 2014
Lead Product(s) : PBT2
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PBT2
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 Study to Determine the Effects of PBT2 on the Pharmacokinetic Profile of Caffeine
Details : PBT2 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 10, 2014
Lead Product(s) : PBT2
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PBT2
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 Study to Determine the Effects of Food on the Pharmacokinetic Profile of PBT2
Details : PBT2 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 08, 2014
Lead Product(s) : PBT2
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PBT2
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
Details : PBT2 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Huntington Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 03, 2012
Lead Product(s) : PBT2
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
